Cellosaurus logo
expasy logo

Cellosaurus SF295/BN50 (CVCL_WV57)

[Text version]
Cell line name SF295/BN50
Accession CVCL_WV57
Resource Identification Initiative To cite this cell line use: SF295/BN50 (RRID:CVCL_WV57)
Comments Population: Caucasian.
Doubling time: 99 hours (PubMed=17984197).
Selected for resistance to: ChEBI; CHEBI:144046; Diflomotecan (BN80915).
Derived from site: In situ; Brain, left temporal lobe; UBERON=UBERON_0002808.
Sequence variations
  • Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
Disease Glioblastoma (NCIt: C3058)
Glioblastoma (ORDO: Orphanet_360)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1690 (SF295)
Sex of cell Female
Age at sampling 67Y
Category Cancer cell line
Publications

PubMed=17984197; DOI=10.1124/mol.107.041178; PMCID=PMC2998068
Liao Z.-Y., Robey R.W., Guirouilh-Barbat J., To K.K.-W., Polgar O., Bates S.E., Pommier Y.
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Mol. Pharmacol. 73:490-497(2008)

Cross-references
Cell line databases/resources cancercelllines; CVCL_WV57
Encyclopedic resources Wikidata; Q98132450
Entry history
Entry creation05-Jul-2019
Last entry update05-Oct-2023
Version number9